Cardiac repair with pluripotent stem cell–derived cardiomyocytes: Proof of concept but new challenges

Hassan Masoudpour, MD, a and Michael A. Laflamme, MD, PhD a,b

From the aMcEwen Centre for Regenerative Medicine, Toronto General Hospital Research Institute, University Health Network; and bDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. M.L. received funding support from the McEwen Centre for Regenerative Medicine, the Toronto General Hospital Research Institute, the Ontario Institute for Regenerative Medicine, and the Medicine by Design/Canada First Research Excellence Fund.

Received for publication April 6, 2017; revisions received May 8, 2017; accepted for publication May 22, 2017; available ahead of print July 6, 2017.

Address for reprints: Michael A. Laflamme, MD, PhD, University Health Network, 101 College St, Room 3-908, Toronto M5G 1L7, Ontario, Canada (E-mail: michael.laflamme@uhnresearch.ca).

J Thorac Cardiovasc Surg 2017;154:945-8
0022-5223/$36.00

Copyright © 2017 by The American Association for Thoracic Surgery
http://dx.doi.org/10.1016/j.jtcvs.2017.05.088

Myocardial infarction (MI) remains among the leading causes of death in the United States and worldwide. 1 Because the heart is a poorly regenerative organ, damaged myocardium is replaced by noncontractile scar tissue that reduces pump capacity and can initiate a process of structural and functional remodeling that often culminates in heart failure. Although there have been remarkable improvements in the medical management of post-MI patients in recent decades, whole-organ transplantation remains the only clinically available means of replacing lost contractile tissue and is the gold-standard treatment for end-stage heart failure. Unfortunately, the supply of donor hearts is inadequate to meet demand and those individuals fortunate enough to receive a heart transplant require close follow-up and lifelong immunosuppression, so many investigators have endeavored to develop cell-based therapies as an alternative strategy to remuscularize injured hearts and restore contractile function. Although the field initially focused on adult stem cells, including various bone marrow-derived cell populations, early clinical experience with these cell types has been generally disappointing,2 and there is now widespread consensus that they are incapable of differentiating into significant quantities of new cardiomyocytes (CMs).3

By contrast, multiple investigators have reported highly scalable methods for deriving phenotypically unambiguous CMs from pluripotent stem cells (PSCs).4 During the past decade, our group and others have shown that PSC-derived CMs can be used to regenerate infarcted hearts in multiple small animal models of MI.5-9 For example, our team has shown that CMs derived from pluripotent human embryonic stem cells (ESCs) can form stable grafts within the infarct region of small animal models and nonhuman primates and that the resultant graft myocardium is capable of electromechanical integration and 1:1 coupling with host tissue.7,8,10

The landmark discovery of induced PSCs (iPSCs) by Takahashi and colleagues11 provided an alternative source of human PSCs that avoids many of the ethical and political objections associated with ESCs. iPSCs are created by reprogramming adult somatic cells into an ESC-like state via the forced expression of pluripotency-related transcription factors (the cocktail of Oct4, Sox2, c-Myc, and Klf4). Although this reprogramming event initially required gene delivery via integrating viral vectors, a number of potentially safer and even nonviral approaches have significantly improved the prospects of iPSC-based therapies.12 Moreover, whereas ESC-based therapies would be allogeneic and require some degree of pharmacologic immunosuppression, iPSC technology could in principle enable autologous cell therapies where there is less risk of immunogenicity. By this strategy, one would create patient-derived iPSCs by reprogramming some readily accessible cell type (eg, dermal fibroblasts) and then guide their differentiation into some useful replacement cells (eg, CMs, neurons, and β-pancreatic cells). Toward this end, an important preclinical study recently reported in Nature by Shiba and colleagues13 provides exciting proof of concept for the use of iPSC-derived CMs (iPSC-CMs) in treating post-MI heart failure, although their work also highlights some significant and unexpected barriers to translation.

Central Message

Intracardiac injection of cardiomyocytes derived from induced pluripotent stem cells mediates beneficial effects on contractile function in a primate infarct model, but immunologic and other issues must still be addressed.

See Editorial Commentary page 949.
In the study, Shiba and colleagues\textsuperscript{13} transplanted major histocompatibility complex (MHC)-matched primate iPSC-CMs in a nonhuman primate subacute MI model (cynomolgus monkeys) and showed that these CMs partially re-muscularized the infarct scar and mediated robust improvements in contractile function. The resultant myocardial grafts survived for up to 3 months, occupied \( \sim 16\% \) of the infarct scar, and eventually became electrically coupled with host myocardium. To demonstrate their capacity for host-graft electrical coupling, the authors borrowed from an approach that had been previously used in transplantation studies with human ESC-CMs in small-animal and primate models\textsuperscript{7,8,10} and delivered cells that had been engineered to stably express a genetically encoded calcium-sensitive fluorescent protein (G-CaMP7.09). As was the case in the earlier work with GCaMP+ human ESC-CM grafts, the primate iPSC-CM grafts in this study exhibited fluorescent transients that occurred in 1:1 synchrony with the host echocardiogram, proving host–graft electromechanical integration. Also encouraging, none of the 5 infarcted monkeys that received MHC-matched iPSC-CMs showed teratoma formation, despite the implantation of 400 million cells per heart. The latter outcome supports earlier work with related PSC-CMs in small-animal and primate models\textsuperscript{7,8,10} and delivered cells directly to outcomes following delivery of PSC-CMs alone in humans. In the latter case, the transplanted cell populations should be devoid of professional antigen-presenting cells present in whole hearts, such as endothelial cells. By comparison, CMs typically express low levels of MHC I antigens and undetectable levels of MHC II antigens.\textsuperscript{16}

The system described by Shiba and colleagues\textsuperscript{13} is ideally suited to help resolve these uncertainties; determine the immunogenicity of PSC-CMs (whether syngeneic or from individuals with varying degrees of immunological mismatch); and explore strategies to overcome immune responses, including conventional immunosuppression or gene-edited universal donor PSCs.\textsuperscript{17,18} Although the authors have only begun to exploit the potential of their system (and their study involved only a small number of animals), their work has already yielded some insights that should inform the progress in the field. First, in a small pilot experiment, they transplanted iPSC-CMs into MHC-mismatched recipients and found that the graft cells were rejected by 1 month posttransplantation despite treatment with conventional immunosuppressant drugs (ie, tacrolimus and methylprednisolone). However, when the authors later transplanted these same donor cells into MHC-matched and similarly immunosuppressed recipients, grafts survived to the planned 3-month time point posttransplantation with no histologic evidence of cellular rejection. Because the authors did not test other immunosuppressant drugs or varying dosages, it remains to be determined precisely what level of immunosuppression would be required to prevent rejection of an MHC-matched iPSC-CM graft or postthoracotomy animals with significant postoperative adhesions. Although this explanation seems plausible, the study as a whole employed a small number of animals (\( n = 5 \) monkeys per group), so the authors were arguably fortunate to detect an effect by either imaging technique. Indeed, whereas this study by Shiba and colleagues\textsuperscript{13} represents exciting first proof of concept for the functional benefits of iPSC-CM transplantation in a large-animal model, follow-up experiments with larger group sizes and a longer duration of follow-up (3-6 months) seem definitely warranted.

Another important advance from this study by Shiba and colleagues\textsuperscript{13} is their description of a highly relevant model system for specifically addressing immunologic issues related to the allotransplantation of PSC-CMs. This is an area of tremendous uncertainty. Most prior work in the field has involved either the xenotransplantation of human PSC derivatives in animal models\textsuperscript{5,7-10} or the allotransplantation of mouse PSC derivatives in mice.\textsuperscript{14,15} Approaches that have limited utility for predicting host immune responses following the allotransplantation of CMs in eventual human patients. Moreover, clinical experience with solid-organ transplantation may not extrapolate directly to outcomes following delivery of PSC-CMs alone in humans. In the latter case, the transplanted cell populations should be devoid of professional antigen-presenting cells present in whole hearts, such as endothelial cells. By comparison, CMs typically express low levels of MHC I antigens and undetectable levels of MHC II antigens.\textsuperscript{16}
if an alternative immunosuppressive regimen might have sufficed to prevent rejection of a mismatched graft.

In addition to the aforementioned concerns about graft cell rejection, the present study by Shiba and colleagues\(^\text{13}\) also highlighted another barrier to translation: The risk of graft-related arrhythmias. Infarcted monkeys receiving iPSC-CMs or vehicle alone underwent periodic Holter echocardiography monitoring (on days –2, +7, +14, +28, +42, +56, +70, and +80 relative to thoracotomy and intracardiac delivery of iPSC-CMs), and all cell recipients exhibited episodes of nonfatal sustained ventricular tachycardia (VT) that were not observed before cell transplantation or in vehicle controls. Despite worrisome bouts of VT up to 240 bpm and multiple instances in which animals spent 100% of a 24-hour monitoring period in VT, these tachyarrhythmias were reportedly well tolerated with no abnormal behavior, syncope episodes, or mortality. The authors reported an interesting time course for these arrhythmias with a peak incidence at ~14 days posttransplantation, followed by a gradual reduction over time (with the incidence of VT declining from 100% of cell recipients at 14 days to 20% by 80 days posttransplantation). Because the morphology, incidence, and time course of these graft-related tachyarrhythmias are qualitatively similar to those previously reported by Chong and colleagues\(^\text{10}\) following the transplantation of human ESC-CMs in another nonhuman primate MI model, VT seems likely to be a generalizable phenomenon that can be expected following any significant remodeling with PSC-CMs in large animals. Importantly, these graft-related arrhythmias were not predicted by earlier PSC-CM transplantation studies in small-animal models.\(^\text{7,8}\) This difference may reflect the suppression of graft cell ectopy by the faster sinus rate of rodent recipients and/or their smaller heart and graft sizes with shorter paths of conduction for re-entrant arrhythmias to arise. To some extent, these same limitations might also apply to the primate model employed by Shiba and colleagues\(^\text{13}\) because these were relatively small, rabbit-sized monkeys (with hearts weighing ~10 g and a sinus rate of ~160 bpm).\(^\text{19,20}\)

### NEXT STEPS
Shiba and colleagues\(^\text{13}\) have provided exciting first proof of concept for the use of PSC-CMs in a large-animal MI model, and they have described a highly relevant platform that should be very useful for addressing immunologic issues with these cells. However, as with any study, there are important limitations to their work that will need to be addressed in future experiments if this therapeutic approach is to advance to clinical use. First and foremost, the field needs to determine the mechanistic basis of tachydystrhythmias observed following iPSC-CM transplantation and define an effective strategy to eliminate them. Even if these graft-related arrhythmias are transient in nature, their occurrence in a patient population already at elevated risk of arrhythmias is obviously unacceptable. As noted above, the small primates in the study by Shiba and colleagues\(^\text{13}\) have a rapid sinus rate that significantly exceeds that of humans and so may mask graft-related arrhythmias that may otherwise occur in patients, so transplantation studies in a larger, slower-rated primate (eg, swine or canine) model may be more informative. Second, whereas this study represents the first demonstration of efficacy with iPSC-CMs in a large-animal model, it will be important to re-examine the functional consequences of iPSC-CM transplantation in a follow-up study involving a larger cohort of animals and a longer duration of follow-up. Indeed, other cell therapies have shown transient beneficial effects that have not persisted to later time points.\(^\text{21}\) Third, as noted above, the authors have described an elegant system for investigating the immunobiology of PSC-CM allografts, but additional experiments will be required to better define the immunogenicity of these cells and to determine the most appropriate immunosuppression regimen with any given degree of MHC mismatch. It would also be useful to know the fate of iPSC-CM grafts in MHC-matched recipients in the absence of immunosuppression. The authors imply that MHC-matched cells would be rejected, but that was never directly tested in the present study. Work to address these immunologic issues would probably be better performed using wild-type cells, rather than iPSC-CMs that have been engineered to express GCaMP, as in the present study. GCaMP is a potential confounder: It is a derivative of the jellyfish green fluorescent protein, which is known to be highly immunogenic.\(^\text{22}\)

Finally, a common limitation of not only this report but also nearly all prior work in the cardiac cell therapy field, is that we have incomplete mechanistic insights into how the transplantation of these cells actually mediate beneficial effects on LV contractile function. Indeed, Shiba and colleagues\(^\text{13}\) did show that their iPSC-CM grafts are capable of electromechanical integration and 1:1 coupling with host myocardium, but this finding does not prove that the salutary effects of iPSC-CM transplantation are direct and result from the formation of new, synchronously activated force-generating units. Other indirect mechanisms cannot be ruled out, including passive mechanical buttressing by the large myocardial implants, reduced wall thinning, activation of endogenous reparative mechanisms, and/or paracrine release of proangiogenic and/or cardioprotective factors.\(^\text{23}\) (The latter mechanism, the paracrine release of factors that promote the salvage of host CMs, has been reported to be particularly important in mediating the beneficial effects of other candidate cell therapies.\(^\text{24}\)) Going forward, Shiba and colleagues\(^\text{13}\) may be able to address some of these potential mechanisms using straightforward histologic end points, perhaps even on existing materials.
(eg, by looking for evidence of increased border zone capillary density or reduced host cell death). Elucidating other potential mechanisms may be more challenging and may even require creation of new tools to better reveal how the graft CMs are operational. Nonetheless, this is a critical issue to resolve that has large implications for translational issues such as the most appropriate timing, dose, and route of cell administration. Shiba and colleagues\textsuperscript{13} have provided compelling evidence that iPSC-CMs can improve contractile function in infarcted hearts, so a critical next step will be to determine precisely how these cells mediate this effect.

Conflict of Interest Statement
Dr Laflamme is a founding investigator, equity holder, and a paid consultant for BlueRock Therapeutics Corp. Dr Masoudpour has nothing to disclose with regard to commercial support.

References